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INTRODUCTION 
Gabapentin (Neurontin) has been on the UK 
market for 1 year and has been on the US market 
for about the same length of time. This is unusual, 
because most new anticonvulsant drugs reach the 
American market much later than the European 
market. Experience with this drug in the US has 
developed rapidly, possibly because of the co- 
incidential withdrawal of Felbamate. Most of the 
experience with this drug pre-marketing was 
obtained through controlled trials: there was very 
little named patient or compassionate patient use 
so that most epileptologists prior to launch had 
very little practical experience of it in ordinary 
clinic use. This was certainly my own situation. 
This conference brought together several ex- 
perienced epileptologists, both from the UK and 
the US, to discuss their post marketing ex- 
perience with Gabapentin. Because of my own 
(and I suspect most other peoples') limited 
clinical experience of this drug (as opposed to 
trial experience) I found the conference particu- 
larly useful. Speakers included Dr Crawford from 
the Special Centre for Epilepsy in York, Dr 
Brown from the David Lewis Centre and Dr 
Roberts of the Dundee Royal Infirmary, Profes- 
sor Pellock of Richmond, Virginia and Professor 
Ramsay from the Centre for Epilepsy of the 
University of Miami. Scientific information was 
provided by Drs Taylor and Frank of Parke- 
Davis. 
What follows is my own idiosyncratic review of 
this Conference. It was a model of what such a 
review Conference about one drug should be: it 
was entirely non-promotional and seemed a 
particularly honest attempt to evaluate the 
present position and possible future use of 
Gabapentin and was a meeting where flank and 
honest discussion was possible. What did I learn 
from it? 
DOES GABAPENTIN WORK? 
The answer to this question is an unqualified yes. 
In patients with partial seizures with or without 
secondary generalization, this drug is clearly 
more effective than placebo (the evidence is 
reviewed in detail by Chadwick1). In the publ- 
ished clinical trials there is good evidence of a 
dose-response relationship with higher doses 
causing a significant increase in seizure control. 
Most speakers felt that the doses used in the early 
double-blind placebo control trials were lower 
than they need have been and in clinical practice 
they used higher doses than those originally used. 
All speakers have found the drug to be effective 
in ordinary clinical use with between 5 and 20% 
of clinic patients they have tried it on becoming 
seizure free and a further proportion having a 
useful reduction in seizure frequency, with a very 
acceptable side-effect profile. The combined 
clinical experience of the speakers covered a large 
number of patients, some with brain damage or 
mental handicap. 
Published data on Gabapentin relates to trials 
in adults with refractory partial seizures (with or 
without secondary generalization). Data on its 
effectiveness in the treatment of primary general- 
ized epilepsy has yet to be published: the 
consensus view at the conference was that it may 
not be very effective in this group of patients 
although occasional patients with primary gene- 
ralized epilepsy may respond well to Gabapentin. 
Clinical trials are obviously necessary to 
determine whether a drug is effective or not but 
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these trials nowadays are so often carried out in 
such a refractory group of patients, and dose 
regimens are so fixed, that it is difficult to 
extrapolate from the results of clinical trial results 
to the general run of patients that one sees in the 
clinic. It is important to remember that the results 
of clinical trials in refractory patients with a 
particular new drug cannot be extrapolated to 
and compared with trial experience with other 
new compounds. The fact that new drug X caused 
50% of patients to achieve a 50% reduction in 
seizure frequency and new drug Y only enabled 
30% of patients to get a 50% reduction in seizure 
frequency does not imply that drug X is therefore 
better than drug Y, since it is quite likely that the 
patients that drug Y was tried on were non- 
responders to drug X. I make this point because 
competition between the various new drugs has 
become somewhat cutthroat and some rather 
misleading claims like this have been put forward. 
HOW DOES IT WORK? 
Gabapentin appears to be an interesting example 
of a 'designer drug' that has been later found to 
work in a way that its designers did not anticipate. 
The drug was synthesized because of its structural 
similarity to gamma minobutyric acid (GABA) 
and its ability to cross the blood-brain barrier. 
Animal work has shown, however, that although 
Gabapentin clearly does get into the brain 
it does not interact with GABAA or GABA, 
receptors and seems to have no effect on GABA 
metabolism. 2 It also has no effect on the other 
classical sites of action of conventional nticon- 
vulsant drugs (such as voltage-dependent sodium 
channels or excitatory neurotransmitter recep- 
tors). There seems to be a specific Gabapentin 
binding site in the brain localized on neuronal cell 
bodies. Gabapentin is transported across the gut 
(and probably across the blood-brain barrier and 
neuronal cell membranes) by amino acid tran- 
sport (system L). Once on its binding site, it 
appears to interact with at least three cytosolic 
enzymes involved with amino acid metabolism. It 
appears to enhance both the degradation and 
synthesis of glutamate indirectly. It is also a weak 
inhibitor of GABA transaminase. Gabapentin 
itself has a structural similarity to L-leucine. The 
anticonvulsant action of Gabapentin may result 
from alteration in the concentration or metabol- 
ism of brain amino acids. It has been suggested 
that this is why it has a unique and potent profile 
of anticonvulsant activity in animal models of 
epilepsy 2.
Much work needs to be done before 
Gabapentin's mode of action is fully understood, 
but it is likely that it works in a completely 
different way from other anticonvulsant drugs. 
There is also a need to explain why the maximum 
anticonvulsant effect (in animal studies) is 
achieved after the drug concentration i  plasma 
and in brain interstitial space has begun to 
decline. The anticonvulsant action of Gabapentin 
may result from delayed biochemical changes that 
require drug to be present at the appropriate site 
for a period of time before significant anticonvul- 
sant activity occurs z. This hypothesis might well 
have implications for how often the drug has to be 
given per day. 
WHAT IS THE DOSE? 
The early double-blind placebo controlled clinical 
trials used doses ranging between 600 and 
1 800mg a day. There was a dose-response 
relationship in terms of increasing efficacy with 
increasing doses. The concensus view of the 
speakers was that the dose can be taken far higher 
than 1 800 mg a day in patients who have begun to 
respond and that sticking to lower doses of the 
drug in line with the early clinical trials may rob 
some patients of full benefit. 
Gabapentin is transported across the gut by 
amino acid transfer: there is some suggestion that 
at very high doses the transfer system saturates. 
This presumably is responsible for the observed 
lack of oral dose proportionality in animals and 
man 2. There was much discussion about what the 
upper dose ceiling should be. The consensus view 
was that 3 600 mg a day should be regarded as the 
upper dose at the moment although one or two 
speakers were prepared to take the dose beyond 
that in selected patients. 
The half-life of Gabapentin is short (5-7 hours) 
which would suggest hat if Gabapentin was a 
conventional drug it should be given at least hree 
times a day. 
There are practical difficulties in giving any 
drug three times a day over a long period of time. 
Some UK speakers indicated that many of their 
patients took it twice a day and it still seemed to 
be effective. Since its anticonvuisant action 
appears to some extent not to be related to serum 
or even brain concentration levels twice daily 
dosage may well be sufficient. It was suggested by 
several speakers that clinical trials should be 
carried out to determine whether thrice daily 
dosing is essential. 
There was much discussion about how rapidly 
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dosage can be escalated. The manufacturers 
recommend a fairly rapid dose escalation, sug- 
gesting dose increases over a week to an initial 
total daily dose of 1 200mg in three divided 
doses 1. Some of the UK speakers (and discussants 
from the floor) suggested that although rapid 
induction perhaps has some advantages, it may 
increase the incidence of side effects. It is clear 
that a proportion of people who use Gabapentin 
initiate treatment with a low starting dose and 
escalate the dosage more slowly, particularly in 
patients on polytherapy or with concomitant 
brain impairment. It was my impression that 
physicians who go for slow escalation are 
prepared to go much higher in terms of the 
eventual ceiling dose: and it may be that in 
prescribing for outpatients (as opposed to pre- 
scribing for patients in institutions) a slower dose 
escalation may be preferred. 
WHAT SIDE EFFECTS MAY BE EXPECTED? 
Gabapentin has achieved a reputation of being a 
drug without side effects. This is not entirely true 
but it certainly does appear to be a drug with few 
or no serious side effects. As with all anticonvul- 
sants it can produce drowsiness, fatigue, dizzi- 
ness, ataxia, nystagmus and occasional headache. 
In the double-blind placebo controlled trials these 
were the six most important side effects which 
occurred significantly more often than with 
placebo ~. However they are usually mild and 
tolerable or can be alleviated by dose reduction 
or by a slower dose increment. Serious, poten- 
tially life threatening, side effects have not been 
reported. 
ARE THERE ANY INTERACTION PROBLEMS 
WITH THIS DRUG? 
There appear to be none. Possibly because of its 
unique pharmacology and mode of action, Gaba- 
pentin does not interact with any other anticon- 
vulsant or with any other important drug (like 
oral contraceptives). In animal studies it appears 
to have no teratogenic effects which is encourag- 
ing. It is unnecessary to measure blood levels. 
WHO SHOULD TRY IT? 
The concensus view of the speakers was that 
Gabapentin is worth trying in any patient with 
partial seizures with or without secondary gene- 
ralization who has proved resistant o conven- 
tional medication. Since it has a low side-ffect 
profile and does not interact with other anticon- 
vulsants it is particularly suited to be an early add 
on drug rather than being used later, and 
speakers were encouraged by the responses they 
had seen in a year's clincial experience with the 
drug. Significant seizure reduction and enhance- 
ment of quality of life occurred in some 30-40% 
of patients in whom it was tried and between 5 
and 20% of patients in whom it was tried became 
seizure free (this is a 'meta analysis' of the clinical 
experience presented at the Conference). It 
cannot yet be recommended for patients with 
intractable primary generalized epilepsy although 
several speakers from the floor indicated that 
they would be prepared to try the drug in such 
patients and there were one or two individual 
case reports of success in this type of patient. 
CONCLUSION 
Gabapentin is clearly effective in some patients 
with partial seizures with or without secondary 
generalization (clinical trials suggest hat partial 
seizures with secondary generalization are par- 
ticularly responsive to this drug). Clincial ex- 
perience with this drug a year after its launch 
suggests that it is well worth trying early in 
patients with resistent epilepsy, particularly as 
some patients that are treated will become seizure 
free. It is particularly effective as an add on drug 
because of its lack of interaction with other 
anticonvulsant compounds and its acceptably low 
side-effect profile. 
The manufacturers were urged to carry out 
trials to determine whether twice daily dosage 
was as effective as thrice daily dosage: there was 
also controversy about whether rapid dose 
escalation was always necessary or advisable and 
further evaulation work in this area needs to be 
undertaken. 
The acid test of any new anticonvulsant drug is 
obviously whether or not it is as effective as other 
compounds in monotherapy. Such trials are 
underway with Gabapentin: since, theoretically, 
Gabapentin has much to recommend it as a 
monotherapy drug the outcome of these trials is 
awaited with interest. Whether or not it is more 
effective than placebo in patients with primary 
generalized epilepsy remains to be seen. There 
were strong suggestions from several speakers 
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that because of its acceptable side-effect profile 
this drug might be particularly helpful in patients 
with mental handicap: formal assessment of its 
use in this area was strongly advised. 
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